Pfizer uses ion PGM platform to carry out "precision medicine" project in Chile

Source: bioexploration 2015-7-14 last week, pharmaceutical giant Pfizer launched the landing project of center of excellence in precision in medicine (CEPM) in Chile In the newly established center, Pfizer will focus on newer, more accurate and non-invasive cancer diagnosis In addition to the $14 million invested by Pfizer in the project, the Chilean Economic Development Agency (CORFO) will also invest $7 million in four years Thermo Fisher is the technical partner of this "precision medical plan" The first phase of the project will use ion PGM, the gene sequencing platform of life technologies, a subsidiary of Thermo Fisher Currently, Thermo Fisher has invested 3 million dollars in the project In a statement, Sylvia Varela, President of Pfizer's cancer business in Latin America, said: Pfizer's first phase of research in CEPM focuses on lung cancer research Currently, there are 1800 to 2100 patients in Chile every year This work is mainly based on molecular diagnosis conducted on a new ngs platform According to Marcela Angulo, technical director of the CORFO, Chile's scientific research capacity is very strong Chile is not only committed to transforming basic knowledge into industry, but also to using it to improve people's lives Through this strategic cooperation, we will further promote the scientific research capacity, development level and innovation of the whole country and Chile's position in the global genome innovation and research sector.